A major metabolite of PGD2 found in human and mouse urine at levels of approximately 1.5 and 8.1 ng/mg creatinine, respectively.

An isotopically enriched form of a PUFA with carbon-13 occurring at positions 1, 2, 3, 4, and 5; used to study metabolic processes related to arachidonic acid by means of mass spectrometry.

An isotopically enriched form of a PUFA standard with carbon-13 occurring at positions 1, 2, 3, 4, and 5; used to study metabolic processes related to arachidonic acid by means of mass spectrometry.

A metabolite of 14,15-LTC4 and 14,15-LTD4 increases vascular permeability of human endothelial cell monolayers with about 10-fold less potency compared LTC4, but approximately 100-fold greater potency than histamine.

A unique LT with weak contractile activity on both guinea pig ileum and pulmonary parenchyma compared to 5-LO-derived LTs; increases vascular permeability of human endothelial cell monolayers with similar potency to that of 5-LO-derived LTs.

LTF4 is a cysteinyl-leukotriene produced in vitro, but not reported to date in vivo. It is formed by the incubation of LTE4 with γ-glutamyl transpeptidase and glutathione. LTF4 is a weak agonist in its ability to contract vascular smooth muscle. The rank order of potency of the…

LTB4 dimethyl amide is a moderate inhibitor of LTB4-induced degranulation of human neutrophils (Ki = 130 nM) and lysozyme release from rat PMNL. LTB4 dimethyl amide appears to be an antagonist of the LTB4 receptor on guinea pig lung membranes.

An internal standard for the quantification of 8-iso PGE2 by GC- or LC-MS.

A 1,3 disubstituted urea derivative of 17(R),18(S)-EpETE that is more metabolically robust and reduces the contractility of cardiomyocytes with improved potency (EC50 fold higher than required for the effect on cardiomyocytes, 1-5 μM CAY10662 exerts weak dose-dependent sEH inhibition.